Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 0.50 |
| ▸ | HTR2B | P41595 | 14/20 | 0.50 |
| ▸ | HTR2A | P28223 | 14/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8588169 | 0.83 | HTR2C (0.46) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL19423526 | 0.80 | GAA (0.47) | HTR2CHTR2B | |
| SCHEMBL2404066 | 0.76 | HTR2C (0.54) | HTR2CHTR2BHTR2ACYP3A4 | |
| SCHEMBL4430758 | 0.76 | HTR2C (0.50) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL11287256 | 0.76 | SLC6A2 (0.44) | HTR2CHTR2BHTR2ACYP3A4TAAR1 | |
| SCHEMBL7601350 | 0.75 | HTR2C (0.42) | HTR2CHTR2BHTR2A | |
| SCHEMBL410563 | 0.75 | P2RX7 (0.43) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL470870 | 0.75 | P2RX7 (0.43) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL15210114 | 0.74 | PKM (0.40) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL5915114 | 0.72 | HTR2C (0.44) | HTR2CHTR2BHTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492794-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082877-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |